Background
Phase III RCT (TAX 324). 501 patients with stage III or IV SCCHN (oral cavity, larynx, oropharynx, or hypopharynx) without distant metastases, who had unresectable tumors, low surgical curability based on advanced T3-4/N2-3 stage, or were organ-preservation candidates. Tested addition of docetaxel to cisplatin + 5-FU induction prior to concurrent chemoradiation.
Interventions and follow up
Arm A (TPF): Docetaxel 75 mg/m² IV day 1 + cisplatin 100 mg/m² IV day 1 + 5-FU 1000 mg/m²/day continuous infusion days 1-4, q3wk × 3 cycles, followed by concurrent chemoradiation with weekly carboplatin AUC 1.5 plus radiotherapy 5 days/week
Arm B (PF): Cisplatin 100 mg/m² IV day 1 + 5-FU 1000 mg/m²/day continuous infusion days 1-4, q3wk × 3 cycles, followed by the same concurrent chemoradiation
Primary endpoint: Overall survival (OS)
mFollow up: Minimum 2 years; 72 months in 2011 Lorch update
Arm B (PF): Cisplatin 100 mg/m² IV day 1 + 5-FU 1000 mg/m²/day continuous infusion days 1-4, q3wk × 3 cycles, followed by the same concurrent chemoradiation
Primary endpoint: Overall survival (OS)
mFollow up: Minimum 2 years; 72 months in 2011 Lorch update
Results
mOS: 71 vs 30 months (TPF vs PF), HR 0.70, 95%CI 0.54-0.90, P=.006
3-yr OS: 62% vs 48% (TPF vs PF)
OS in resectable tumors: NR vs 42 months, HR 0.52, 95%CI 0.32-0.84, P=.007
mOS in unresectable tumors: 40 vs 21 months, HR 0.68, 95%CI 0.45-1.01, P=.06
Locoregional control: better with TPF, P=.04
Distant metastases: no significant difference, P=.14
Lorch 2011 long-term update (PMID 21233014, mFU 72 mo): mOS 70.6 vs 34.8 months, HR 0.74, 95%CI 0.58-0.94; 5-yr OS 52% vs 42%
3-yr OS: 62% vs 48% (TPF vs PF)
OS in resectable tumors: NR vs 42 months, HR 0.52, 95%CI 0.32-0.84, P=.007
mOS in unresectable tumors: 40 vs 21 months, HR 0.68, 95%CI 0.45-1.01, P=.06
Locoregional control: better with TPF, P=.04
Distant metastases: no significant difference, P=.14
Lorch 2011 long-term update (PMID 21233014, mFU 72 mo): mOS 70.6 vs 34.8 months, HR 0.74, 95%CI 0.58-0.94; 5-yr OS 52% vs 42%
Adverse events
Hematologic (TPF vs PF): grade ≥3 neutropenia 83% vs 56%; febrile neutropenia 12% vs 7%; neutropenic infection 12% vs 8%
Non-hematologic (TPF vs PF): stomatitis/mucositis 21% vs 27%; nausea 14% vs 14%; esophagitis 13% vs 9%; anorexia 12% vs 12%; treatment delays due to toxicity 29% vs 65%
Non-hematologic (TPF vs PF): stomatitis/mucositis 21% vs 27%; nausea 14% vs 14%; esophagitis 13% vs 9%; anorexia 12% vs 12%; treatment delays due to toxicity 29% vs 65%
Conclusions
Induction TPF followed by concurrent carboplatin chemoradiation significantly prolonged OS compared with PF induction followed by the same chemoradiation in locally advanced SCCHN, with a durable benefit at 5 years, establishing TPF as the preferred induction regimen when induction is used.
Key Limitations
TAX 324 compared two induction regimens but did not test induction TPF against upfront concurrent chemoradiation, so it does not establish a survival benefit for the induction strategy itself; subsequent trials (PARADIGM, DeCIDE) failed to show induction superiority over concurrent chemoradiation alone. Conducted in a largely HPV-unselected, heavy-smoking era population.
Clinical Context
TAX 324 differs from TAX 323 by using 3 cycles (vs 4) at higher cisplatin (100 vs 75 mg/m²) and 5-FU (1000 vs 750 mg/m²/day) doses, with concurrent weekly carboplatin chemoradiation rather than radiotherapy alone. ESMO endorses TPF as the induction regimen of choice when induction is selected; however, induction is not routine, as concurrent chemoradiation remains the definitive standard for most locally advanced SCCHN.